Genetic Modulation of Glaucoma
青光眼的基因调控
基本信息
- 批准号:8269646
- 负责人:
- 金额:$ 37.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-06-01 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:AllelesAtrophicBioinformaticsBiological AssayBlindnessCandidate Disease GeneCell CountClinicalDataData SetDiseaseDisease modelEvaluationEyeEye diseasesGenesGeneticGenotypeGlaucomaHaplotypesHumanHuman ChromosomesInvestigationIrisIris DiseasesLaboratoriesLeadLinkLiteratureMapsMethodsMicroarray AnalysisMolecularMolecular ModelsMusMutationOpen-Angle GlaucomaOptic NerveOutcomeParentsPatientsPenetrancePhenotypePhysiologic Intraocular PressurePigmentsPredispositionQuantitative Trait LociReadingRecombinant Inbred StrainResearchResearch PersonnelResistanceRetinaSeveritiesSeverity of illnessStatistical ModelsSurveysTestingTranslationsVariantWhole-Genome Shotgun SequencingWorkage relatedauthoritycohortexpectationexperienceganglion cellmolecular modelingmutanttrait
项目摘要
In this proposal, we use our enlarged set of BXD recombinant inbred strains to identify gene loci that are
involved in modulating the severity of glaucoma. Our approach combines a thorough clinical and laboratory
examination, and microarray analysis of the entire set of 81 BXD lines generated over the last 10 years with the
express purpose of studying the genetics of eye disease and glaucoma. One of the parental strains of BXD,
DBA/2J, develop an age-related glaucoma that is preceded by iris atrophy and pigment dispersion. While
mutant alleles of two genes, Tryp1 and Gpnmb, cause the iris disease in D2, the literature strongly suggests that
these mutations are not sufficient to cause glaucoma. Specifically, introgression of both mutant alleles onto
C57BL/6J, the other parent strain of BXD, results in a marked resistance to optic nerve damage. This indicates
that genes other than those that cause pigment dispersion influence the glaucomatous phenotype. The current
proposal describes a unique opportunity to define the modifying loci. In Aim 1, we test the hypothesis that the
combined mutations in Tryp1 and Gpnmb are not sufficient to cause all aspects of the glaucoma phenotype. If
our hypothesis is true, we expect to see that the severity of disease is not solely dependent on the two mutant
alleles. We have already identified multiple BXD strains in which IOP and genetic diplotype are not correlated.
As we systematically examine all BXD strains and establish relations between phenotype and diplotype, we
fully expect to find additional strains that defy expectations of a simple two-locus disease model. In Aim 2, we
define loci and genes that modulate glaucoma severity. To do so, we will identify and evaluate candidate
genes within loci that modulate the severity of the glaucoma phenotype. We will exploit our new whole
genome shotgun sequence for D2 (about >50x short read coverage generated at UTHSC in 2009) along with
massive whole eye and whole retina expression datasets that we have also generated as a prelude to this work.
We expect to efficiently nominate and evaluate candidate glaucoma genes using state-of-the-art bioinformatic
methods and conventional molecular assays. In Aim 3, we use bidirectional translation. We test the
translational validity of mouse candidates from Aim 2 using cohorts of human glaucoma patients. Dr. J. Wiggs
and colleagues will perform focused gene association studies using candidate glaucoma genes nominated in
Aim 2. Specifically, we use association analyses of markers encompassing syntenic regions of human
chromosomes. In reciprocal reverse translation, we (MMJ and LL) will evaluate known, new, and candidate
glaucoma genes from clinical cohorts and determine if and how these variants are associated with glaucoma-
associated traits in BXDs. Combining the top priority gene candidates from both mouse and human glaucoma
studies, we will generate molecular and statistical models of susceptibility candidate genes, linked
phenotypes, and associated mechanisms.
在这个建议中,我们使用我们扩大的BXD重组近交系来鉴定基因位点,
参与调节青光眼的严重程度。我们的方法结合了全面的临床和实验室
检查,和微阵列分析的81个BXD系在过去10年中产生的整个集合,
表达了研究眼病和青光眼遗传学的目的。BXD的亲本菌株之一,
DBA/2 J,发展为年龄相关性青光眼,之前有虹膜萎缩和色素分散。而
两个基因Tryp 1和Gpnmb的突变等位基因导致D2的虹膜疾病,文献强烈表明,
这些突变不足以引起青光眼。具体地,将两种突变等位基因渐渗到
C57 BL/6 J是BXD的另一个亲本菌株,对视神经损伤具有显著的抗性。这表明
除了那些引起色素分散的基因外,其他基因也会影响青光眼的表型。当前
提案描述了一个独特的机会来定义修饰位点。在目标1中,我们测试了假设,
Tryp 1和Gpnmb的组合突变不足以引起青光眼表型的所有方面。如果
我们的假设是正确的,我们希望看到疾病的严重程度不仅仅取决于两个突变体,
等位基因我们已经鉴定了多个BXD菌株,其中IOP和遗传双倍型不相关。
当我们系统地检查所有BXD菌株并建立表型和双体型之间的关系时,
完全期望找到其他菌株,违背了简单的两个基因座疾病模型的期望。在目标2中,
确定调节青光眼严重程度的基因座和基因。为此,我们将确定和评估候选人
调节青光眼表型严重程度的基因座内的基因。我们将利用我们的新整体
D2的基因组鸟枪测序(2009年UTHSC产生的短读段覆盖率约> 50倍),连同沿着
作为这项工作的前奏,我们还生成了大量的全眼和全视网膜表达数据集。
我们希望利用最先进的生物信息学技术有效地提名和评估候选青光眼基因。
方法和常规分子测定。在目标3中,我们使用双向翻译。我们测试的
使用人类青光眼患者的群组对来自Aim 2的小鼠候选物的翻译有效性进行验证。J. Wiggs博士
和同事们将使用提名的候选青光眼基因进行集中的基因关联研究,
目标2.具体地说,我们使用的关联分析的标志物涵盖同线区域的人类
染色体在相互反向翻译中,我们(MMJ和LL)将评估已知、新和候选
青光眼基因,并确定这些变异是否以及如何与青光眼相关-
BXD中的相关特征。结合小鼠和人类青光眼的最优先候选基因
研究,我们将产生易感性候选基因的分子和统计模型,
表型和相关机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MONICA M JABLONSKI其他文献
MONICA M JABLONSKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MONICA M JABLONSKI', 18)}}的其他基金
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
- 批准号:
9912475 - 财政年份:2020
- 资助金额:
$ 37.49万 - 项目类别:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
- 批准号:
10374760 - 财政年份:2020
- 资助金额:
$ 37.49万 - 项目类别:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
- 批准号:
10597097 - 财政年份:2020
- 资助金额:
$ 37.49万 - 项目类别:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
- 批准号:
10542485 - 财政年份:2020
- 资助金额:
$ 37.49万 - 项目类别:
相似海外基金
Progression of Early Atrophic Lesions in Age-related Macular degeneration
年龄相关性黄斑变性早期萎缩性病变的进展
- 批准号:
10635325 - 财政年份:2023
- 资助金额:
$ 37.49万 - 项目类别:
In vivo Identification of Pre-Atrophic Brain Neurodegeneration in Prodromal Alzheimer Disease with Quantitative Gradient Recalled Echo MRI
利用定量梯度回忆回波 MRI 体内鉴定阿尔茨海默病前驱期的萎缩前脑神经变性
- 批准号:
10448152 - 财政年份:2022
- 资助金额:
$ 37.49万 - 项目类别:
The Development and Rescue of an Atrophic Nonunion Model
萎缩性骨不连模型的开发和挽救
- 批准号:
10007577 - 财政年份:2019
- 资助金额:
$ 37.49万 - 项目类别:
The Development and Rescue of an Atrophic Nonunion Model
萎缩性骨不连模型的开发和挽救
- 批准号:
10242918 - 财政年份:2019
- 资助金额:
$ 37.49万 - 项目类别:
Analysis of the role of AMPK in the retina for the development of a novel treatment for atrophic age-related macular degeneration
分析 AMPK 在视网膜中的作用,以开发治疗萎缩性年龄相关性黄斑变性的新方法
- 批准号:
18K09457 - 财政年份:2018
- 资助金额:
$ 37.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Regeneration of atrophic salivary glands by reconstructing tissue macrophages using amniotic fluid-derived cells
利用羊水来源的细胞重建组织巨噬细胞来再生萎缩的唾液腺
- 批准号:
19K21370 - 财政年份:2018
- 资助金额:
$ 37.49万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
The study to detect early-stage pancreatic cancer based on the data from molecular biology about the atrophic acinar cell surrounding carcinoma in situ.
该研究基于原位癌周围萎缩性腺泡细胞的分子生物学数据来检测早期胰腺癌。
- 批准号:
18K07897 - 财政年份:2018
- 资助金额:
$ 37.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Multiple control and visualization of self-somatic- stem cells for atrophic jaw bone augmentation
用于萎缩颌骨增量的自体干细胞的多重控制和可视化
- 批准号:
17H04394 - 财政年份:2017
- 资助金额:
$ 37.49万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Delivery of concentrated peripheral blood derived EPCs and functional miRNAs for atrophic salivary gland regeneration
输送浓缩的外周血来源的 EPC 和功能性 miRNA 以促进萎缩唾液腺再生
- 批准号:
17K17272 - 财政年份:2017
- 资助金额:
$ 37.49万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Development of novel oligonucleotide therapeutics using functional liposomes for atrophic muscular disorder
使用功能性脂质体开发治疗萎缩性肌肉疾病的新型寡核苷酸疗法
- 批准号:
16K20646 - 财政年份:2016
- 资助金额:
$ 37.49万 - 项目类别:
Grant-in-Aid for Young Scientists (B)